NASDAQ:GILD

Gilead Sciences Stock Forecast, Price & News

$65.11
+0.09 (+0.14 %)
(As of 04/9/2021 07:43 PM ET)
Add
Compare
Today's Range
$64.24
Now: $65.11
$65.25
50-Day Range
$61.40
MA: $64.22
$66.44
52-Week Range
$56.56
Now: $65.11
$85.79
Volume5.85 million shs
Average Volume8.49 million shs
Market Capitalization$81.98 billion
P/E Ratio67.12
Dividend Yield4.36%
Beta0.51
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; and Bristol-Myers Squibb Company. The company was founded in 1987 and is headquartered in Foster City, California.
Gilead Sciences logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GILD
CUSIP37555810
Phone650-574-3000
Employees13,600
Year Founded1987

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.45 billion
Cash Flow$7.72 per share
Book Value$17.90 per share

Profitability

Net Income$5.39 billion

Miscellaneous

Outstanding Shares1,259,056,000
Market Cap$81.98 billion
Next Earnings Date4/29/2021 (Estimated)
OptionableOptionable

Headlines

Gilead Sciences Quant Upgrade Got Me Thinking
March 31, 2021 |  realmoney.thestreet.com
Gilead's (GILD) Breast Cancer Drug MAA Validated by EMA
March 29, 2021 |  finance.yahoo.com
U.S. must remain ‘worried about variants’: Doctor
March 24, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

2.76 out of 5 stars

Medical Sector

3rd out of 2,011 stocks

Biological Products, Except Diagnostic Industry

1st out of 176 stocks

Analyst Opinion: 4.3Community Rank: 3.3Dividend Strength: 3.3Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
$65.11
+0.09 (+0.14 %)
(As of 04/9/2021 07:43 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

Is Gilead Sciences a buy right now?

24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 1 sell rating, 9 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Gilead Sciences stock.
View analyst ratings for Gilead Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than Gilead Sciences?

Wall Street analysts have given Gilead Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Gilead Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Gilead Sciences
.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) released its quarterly earnings results on Thursday, February, 4th. The biopharmaceutical company reported $2.19 earnings per share for the quarter, beating the Zacks' consensus estimate of $2.15 by $0.04. The biopharmaceutical company earned $7.42 billion during the quarter, compared to analysts' expectations of $7.11 billion. Gilead Sciences had a net margin of 5.48% and a trailing twelve-month return on equity of 37.77%.
View Gilead Sciences' earnings history
.

How has Gilead Sciences' stock been impacted by Coronavirus?

Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GILD shares have decreased by 11.7% and is now trading at $65.11.
View which stocks have been most impacted by COVID-19
.

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Thursday, February 4th. Shareholders of record on Monday, March 15th will be given a dividend of $0.71 per share on Tuesday, March 30th. This represents a $2.84 annualized dividend and a dividend yield of 4.36%. The ex-dividend date is Friday, March 12th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.68.
View Gilead Sciences' dividend history
.

Is Gilead Sciences a good dividend stock?

Gilead Sciences pays an annual dividend of $2.84 per share and currently has a dividend yield of 4.36%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Gilead Sciences does not yet have a strock track record of dividend growth. The dividend payout ratio of Gilead Sciences is 46.25%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 40.51% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.
View Gilead Sciences' dividend history.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences updated its FY21 earnings guidance on Thursday, February, 4th. The company provided earnings per share guidance of $6.75-7.45 for the period, compared to the Thomson Reuters consensus estimate of $6.90. The company issued revenue guidance of $23.70-25.10 billion, compared to the consensus revenue estimate of $24.49 billion.

What price target have analysts set for GILD?

24 brokerages have issued twelve-month target prices for Gilead Sciences' stock. Their forecasts range from $61.00 to $625.00. On average, they expect Gilead Sciences' stock price to reach $97.23 in the next year. This suggests a possible upside of 49.3% from the stock's current price.
View analysts' price targets for Gilead Sciences
or view top-rated stocks among Wall Street analysts.

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the following people:
  • Mr. Daniel P. O'Day, Chairman & CEO (Age 57, Pay $10.86M)
  • Mr. Andrew D. Dickinson, Exec. VP & CFO (Age 51, Pay $6.91M) (LinkedIn Profile)
  • Mr. Brett A. Pletcher, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 52, Pay $2.14M) (LinkedIn Profile)
  • Ms. Johanna Mercier, Chief Commercial Officer (Age 51, Pay $2.55M) (LinkedIn Profile)
  • Dr. Merdad V. Parsey M.D., Ph.D., Chief Medical Officer (Age 57, Pay $1.12M) (LinkedIn Profile)
  • Ms. Diane E. Wilfong, Sr. VP, Corp. Controller & Chief Accounting Officer (Age 59)
  • Ms. Jyoti K. Mehra, Exec. VP of HR (LinkedIn Profile)
  • Dr. William A. Lee, Exec. VP of Research (Age 66)
  • Dr. Taiyin Yang, Exec. VP of Pharmaceutical Devel. & Manufacturing (Age 67)
  • Dr. Diana M. Brainard M.D., Sr. VP of HIV & Emerging Viral Infections (Age 49)

What is Daniel O’Day's approval rating as Gilead Sciences' CEO?

107 employees have rated Gilead Sciences CEO Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among Gilead Sciences' employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Gilead Sciences' key competitors?

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), The Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Confluence Investment Management LLC (0.09%), State of Alaska Department of Revenue (0.04%), Nexus Investment Management ULC (0.02%), Pacer Advisors Inc. (0.02%), Liberty One Investment Management LLC (0.01%) and Foundation Resource Management Inc. (0.01%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John Francis Cogan, Merdad Parsey and Olsen Per Wold.
View institutional ownership trends for Gilead Sciences
.

Which major investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Fulton Bank N.A., First Financial Bank Trust Division, NuWave Investment Management LLC, Neville Rodie & Shaw Inc., First National Bank of Mount Dora Trust Investment Services, Jacobs & Co. CA, and Indiana Trust & Investment Management CO. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Diane E Wilfong, Javier Rodriguez, John Francis Cogan, and Merdad Parsey.
View insider buying and selling activity for Gilead Sciences
or view top insider-selling stocks.

Which major investors are buying Gilead Sciences stock?

GILD stock was acquired by a variety of institutional investors in the last quarter, including Liberty One Investment Management LLC, Confluence Investment Management LLC, Thomasville National Bank, Everence Capital Management Inc., Nexus Investment Management ULC, F&V Capital Management LLC, Private Asset Management Inc., and Curbstone Financial Management Corp.
View insider buying and selling activity for Gilead Sciences
or or view top insider-buying stocks.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $65.11.

How much money does Gilead Sciences make?

Gilead Sciences has a market capitalization of $81.98 billion and generates $22.45 billion in revenue each year. The biopharmaceutical company earns $5.39 billion in net income (profit) each year or $6.14 on an earnings per share basis.

How many employees does Gilead Sciences have?

Gilead Sciences employs 13,600 workers across the globe.

Does Gilead Sciences have any subsidiaries?

The following companies are subsidiares of Gilead Sciences: Arresto BioSciences, Asegua Therapeutics LLC, Bristol-Myers Squibb and Gilead Sciences Limited, CGI Pharmaceuticals, CV Therapeutics, Calistoga Pharmaceuticals, Cell Design Labs, Corus Pharma, Cytopia Pty. Ltd., EpiTherapeutics ApS, Epitherapeutics, Forty Seven, Fosun Pharma Kite Biotechnology Co. Ltd., Gilead Alberta LLC, Gilead Alberta ULC, Gilead Apollo LLC, Gilead Apollo Unlimited Company, Gilead Biopharmaceutics Ireland UC, Gilead Biopharmaceutics US LLC, Gilead Calistoga LLC, Gilead Connecticut Inc., Gilead Holdings LLC, Gilead Ireland Research UC, Gilead Oncology Ireland UC, Gilead Pharmasset LLC, Gilead Sciences (NZ), Gilead Sciences (Shanghai) Consulting Co. Ltd., Gilead Sciences Americas S. de R.L., Gilead Sciences Argentina S.R.L., Gilead Sciences Belgium BVBA, Gilead Sciences Canada Inc., Gilead Sciences Denmark ApS, Gilead Sciences Europe Limited, Gilead Sciences Farmacêutica do Brasil Ltda., Gilead Sciences Finland Oy, Gilead Sciences GesmbH., Gilead Sciences GmbH, Gilead Sciences Hangzhou Pharmaceutical Co. Ltd., Gilead Sciences Hellas EPE, Gilead Sciences Holding LLC, Gilead Sciences Hong Kong Limited, Gilead Sciences India Private Limited, Gilead Sciences International Limited, Gilead Sciences Ireland UC, Gilead Sciences Israel Limited, Gilead Sciences KK, Gilead Sciences Korea Limited, Gilead Sciences LLC, Gilead Sciences Lda., Gilead Sciences Limited, Gilead Sciences Luxembourg S.a.r.l., Gilead Sciences Malaysia Sdn. Bhd., Gilead Sciences Mexico S. de R.L. de C.V., Gilead Sciences Netherlands BV, Gilead Sciences Norway AS, Gilead Sciences Poland Sp. z o.o., Gilead Sciences Pty. Ltd., Gilead Sciences Russia LLC, Gilead Sciences S.L., Gilead Sciences S.r.l., Gilead Sciences SAS, Gilead Sciences Shanghai Pharmaceutical Technology Co. Ltd., Gilead Sciences Singapore Pte. Ltd., Gilead Sciences Slovakia s.r.o., Gilead Sciences South Africa (Pty) Ltd., Gilead Sciences Sweden AB, Gilead Sciences Switzerland Sarl, Gilead Sciences YM Australia Pty. Ltd., Gilead Sciences llac Ticaret Limited Sirketi, Gilead Sciences s.r.o., Gilead Therapeutics A1 Unlimited Company, Gilead Therapeutics A2 Unlimited Company, Gilead YM ULC, Immunomedics, KP EU C.V., Kite Pharma, Kite Pharma EU B.V., Kite Pharma Inc., Kite Pharma LLC, Kite Pharma UK Ltd, MYR, Myogen, NeXstar Pharmaceuticals, Nimbus Apollo, Nycomed, Pharmasset, Phenex Pharmaceuticals, Raylo Chemicals, Tri-Supply Limited, Triangle Pharmaceuticals, YM BioSciences, YM BioSciences Australia Pty. Ltd., and neoKite Inc..

When was Gilead Sciences founded?

Gilead Sciences was founded in 1987.

What is Gilead Sciences' official website?

The official website for Gilead Sciences is www.gilead.com.

Where are Gilead Sciences' headquarters?

Gilead Sciences is headquartered at 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]


This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.